{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T19:07:13Z","timestamp":1779217633812,"version":"3.51.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,4,16]],"date-time":"2022-04-16T00:00:00Z","timestamp":1650067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,16]],"date-time":"2022-04-16T00:00:00Z","timestamp":1650067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Although the benefit of androgen deprivation therapy (ADT) continuation in metastatic castration-resistant prostate cancer (mCRPC) remains controversial, clinical evidence is lacking. Recent results indicated that treatment with abiraterone acetate (AA) plus prednisone (P) further suppresses serum testosterone levels over ADT alone, suggesting that continuation of ADT in the treatment of mCRPC may not be necessary.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this exploratory phase 2 study, mCRPC patients were randomized with a 1:1 ratio to receive either continued ADT plus AA\u2009+\u2009P (Arm A) or AA\u2009+\u2009P alone (Arm B). The primary endpoint was the rate of radiographic progression-free survival (rPFS) at month 12. Secondary endpoints included PSA-response rate, objective response, time to PSA progression and safety.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 68 patients were equally randomized between the two study arms. Median testosterone-levels remained below castrate-levels throughout treatment in all patients. According to the intention-to-treat analysis the rPFS rate was 0.84 in Arm A and 0.89 in Arm B. Moderate and severe treatment-emergent adverse events were reported for 72% of the patients in Arm A and for 85% of the patients in Arm B.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>AA\u2009+\u2009P treatment without ADT may be effective in mCRPC patients and ADT may not be necessary in patients receiving AA\u2009+\u2009P.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41391-022-00533-6","type":"journal-article","created":{"date-parts":[[2022,4,16]],"date-time":"2022-04-16T05:02:48Z","timestamp":1650085368000},"page":"778-784","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["LHRH sparing therapy in patients with chemotherapy-na\u00efve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial"],"prefix":"10.1038","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1562-5364","authenticated-orcid":false,"given":"Carsten-Henning","family":"Ohlmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"J\u00e4schke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Jaehnig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Krege","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Gschwend","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidrun","family":"Rexer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerstin","family":"Junker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Zillmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"R\u00fcssel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Hellmis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Suttmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Marin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"H\u00fcbner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Mathers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jochen","family":"Glei\u00dfner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Scheffler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Feyerabend","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Telle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg","family":"Klier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"St\u00f6ckle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,16]]},"reference":[{"key":"533_CR1","doi-asserted-by":"publisher","first-page":"63","DOI":"10.14740\/wjon1191","volume":"10","author":"P Rawla","year":"2019","unstructured":"Rawla P. Epidemiology of Prostate Cancer. World J Oncol. 2019;10:63\u201389.","journal-title":"World J Oncol"},{"key":"533_CR2","doi-asserted-by":"publisher","first-page":"7263","DOI":"10.2147\/OTT.S117176","volume":"9","author":"AS Merseburger","year":"2016","unstructured":"Merseburger AS, Alcaraz A, von Klot CA. Androgen deprivation therapy as backbone therapy in the management of prostate cancer. OncoTargets Ther. 2016;9:7263\u201374.","journal-title":"OncoTargets Ther"},{"key":"533_CR3","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.eururo.2008.01.049","volume":"53","author":"FH Schr\u00f6der","year":"2008","unstructured":"Schr\u00f6der FH. Progress in understanding androgen-independent prostate cancer (AIPC): a review of potential endocrine-mediated mechanisms. Eur Urol. 2008;53:1129\u201337.","journal-title":"Eur Urol"},{"key":"533_CR4","doi-asserted-by":"publisher","first-page":"3742","DOI":"10.1200\/JCO.2008.20.0642","volume":"27","author":"G Attard","year":"2009","unstructured":"Attard G, Reid AHM, A\u2019Hern R, Parker C, Oommen NB, Folkerd E, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol. 2009;27:3742\u20138.","journal-title":"J Clin Oncol"},{"key":"533_CR5","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS de Bono","year":"2011","unstructured":"de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl J Med. 2011;364:1995\u20132005.","journal-title":"N. Engl J Med"},{"key":"533_CR6","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","volume":"16","author":"CJ Ryan","year":"2015","unstructured":"Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PFA, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16:152\u201360.","journal-title":"Lancet Oncol"},{"key":"533_CR7","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","volume":"20","author":"K Fizazi","year":"2019","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20:686\u2013700.","journal-title":"Lancet Oncol"},{"key":"533_CR8","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1200\/JCO.2017.75.2998","volume":"36","author":"G Heller","year":"2018","unstructured":"Heller G, McCormack R, Kheoh T, Molina A, Smith MR, Dreicer R, et al. Circulating tumor cell number as a response measure of prolonged survival for metastatic castration-resistant prostate cancer: a comparison with prostate-specific antigen across five randomized phase iii clinical trials. J Clin Oncol. 2018;36:572\u201380.","journal-title":"J Clin Oncol"},{"key":"533_CR9","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl J Med. 2013;368:138\u201348.","journal-title":"N. Engl J Med"},{"key":"533_CR10","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1200\/JCO.2009.24.1281","volume":"28","author":"CJ Ryan","year":"2010","unstructured":"Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff P, Raynaud F, et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol. 2010;28:1481\u20138.","journal-title":"J Clin Oncol"},{"key":"533_CR11","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/pros.20341","volume":"66","author":"H Kaku","year":"2006","unstructured":"Kaku H, Saika T, Tsushima T, Ebara S, Senoh T, Yamato T, et al. Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer. Prostate. 2006;66:439\u201344.","journal-title":"Prostate"},{"key":"533_CR12","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1080\/00365590600641533","volume":"40","author":"T Kobayashi","year":"2006","unstructured":"Kobayashi T, Nishizawa K, Mitsumori K. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer. Scand J Urol Nephrol. 2006;40:198\u2013203.","journal-title":"Scand J Urol Nephrol"},{"key":"533_CR13","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1002\/pros.21305","volume":"71","author":"J Pinski","year":"2011","unstructured":"Pinski J, Xiong S, Wang Q, Stanczyk F, Hawes D, Liu SV. Effect of luteinizing hormone on the steroidogenic pathway in prostate cancer. Prostate. 2011;71:892\u20138.","journal-title":"Prostate"},{"key":"533_CR14","doi-asserted-by":"publisher","first-page":"5844","DOI":"10.1158\/1078-0432.CCR-11-0644","volume":"17","author":"JL Mohler","year":"2011","unstructured":"Mohler JL, Titus MA, Wilson EM. Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone. Clin Cancer Res. 2011;17:5844\u20139.","journal-title":"Clin Cancer Res"},{"key":"533_CR15","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","volume":"71","author":"P Cornford","year":"2017","unstructured":"Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71:630\u201342.","journal-title":"Eur Urol"},{"key":"533_CR16","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00345-014-1406-2","volume":"33","author":"AS Merseburger","year":"2015","unstructured":"Merseburger AS, Hammerer P, Rozet F, Roumegu\u00e8re T, Caffo O, da Silva FC, et al. Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy? World J Urol. 2015;33:1079\u201385.","journal-title":"World J Urol"},{"key":"533_CR17","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N. Engl J Med. 2017;377:352\u201360.","journal-title":"N. Engl J Med"},{"key":"533_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-017-2195-x","volume":"18","author":"C-H Ohlmann","year":"2017","unstructured":"Ohlmann C-H, J\u00e4schke M, Jaehnig P, Krege S, Gschwend J, Rexer H, et al. Abiraterone acetate plus LHRH therapy versus abiraterone acetate while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-na\u00efve, castration-resistant prostate cancer (SPARE): study protocol for a randomized controlled trial. Trials. 2017;18:457.","journal-title":"Trials"},{"key":"533_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5709-y","volume":"23","author":"G Werutsky","year":"2019","unstructured":"Werutsky G, Maluf FC, Cronemberger EH, Carrera Souza V, Dos Santos Martins SP, Peixoto F, et al. The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels. BMC Cancer. 2019;23:487.","journal-title":"BMC Cancer"},{"key":"533_CR20","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1038\/sj.bjc.6601879","volume":"90","author":"A O\u2019Donnell","year":"2004","unstructured":"O\u2019Donnell A, Judson I, Dowsett M, Raynaud F, Dearnaley D, Mason M, et al. Hormonal impact of the 17alpha-hydroxylase\/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer. 2004;90:2317\u201325.","journal-title":"Br J Cancer"},{"key":"533_CR21","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/pcan.2014.8","volume":"17","author":"CJ Ryan","year":"2014","unstructured":"Ryan CJ, Peng W, Kheoh T, Welkowsky E, Haqq CM, Chandler DW, et al. Androgen dynamics and serum PSA in patients treated with abiraterone acetate. Prostate Cancer Prostatic Dis. 2014;17:192\u20138.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"533_CR22","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/S1470-2045(17)30906-3","volume":"19","author":"BA Teply","year":"2018","unstructured":"Teply BA, Wang H, Luber B, Sullivan R, Rifkind I, Bruns A, et al. Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. Lancet Oncol. 2018;19:76\u201386.","journal-title":"Lancet Oncol"}],"updated-by":[{"DOI":"10.1038\/s41391-023-00682-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T00:00:00Z","timestamp":1685404800000}}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-022-00533-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-022-00533-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-022-00533-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T06:03:27Z","timestamp":1685513007000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-022-00533-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,16]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["533"],"URL":"https:\/\/doi.org\/10.1038\/s41391-022-00533-6","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41391-023-00682-2","asserted-by":"object"}]},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,16]]},"assertion":[{"value":"4 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2022","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Missing Open Access funding information has been added in the Funding Note.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2023","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41391-023-00682-2","URL":"https:\/\/doi.org\/10.1038\/s41391-023-00682-2","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interests other than the financial support of the trial by Janssen-Cilag GmbH, Germany.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki approved by the trial-leading Ethics Committee of the Saarland (reference number 143\/13) and the Ethics Committees of each trial site. All patients gave written informed consent prior to participation in the trial.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}